Dendreon slides on Provenge sales miss

Shares of Dendreon Corp. (NASDAQ:DNDN) slid $0.71 (15%) to $4.03 on Thursday after the company reported 1Q13 net revenues of prostate cancer drug Provenge sipuleucel-T -- the company's sole marketed p...